Rolapitant Gains FDA Approval for CINV

Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.

The FDA today approved rolapitant (Varubi) to prevent delayed phase chemotherapy-induced nausea and vomiting, which are commonly in cancer patients receiving chemotherapy.

The substance P/neurokinin-1 receptor antagonist rolapitant has been approved in adults for use in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing cancer chemotherapy according to the FDA's press release.

“Chemotherapy-induced nausea and vomiting remains a major issue that can disrupt patients' lives and sometimes their therapy,” said Amy Egan, MD, MPH, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. “Today’s approval provides cancer patients with another treatment option for the prevention of the delayed phase of nausea and vomiting caused by chemotherapy.”

Read the cmplete press release here: